BioSpace News Archive

Companies selling laser and other optical products into the global machine tool sector should expect a decline in sales in 2019 near 10%, compared to 2018.

Science Exchange, whose technology platform is used by research organizations to order and manage outsourced R&D services, announced a strategic partnership with Brex, the corporate card built for scaling businesses.

The Kids for Kids Foundation recently visited St. Jude Children’s Research Hospital in Memphis, Tennessee, for the unveiling of the Kids for Kids Family Room located within the Tri Delta Place patient housing facility.

€400,000 awarded to each of 12 recipients: The eleventh annual awards recognized the works of twelve researchers and their pivotal contributions in eight categories, from rising sea levels to the discovery of the microbiome

Iconic buildings partner with the National Safety Council to raise awareness of preventable deaths

EXUMA Biotechnology, a clinical-stage biotechnology company discovering and developing CAR-T products for solid tumors and affiliate of F1 Oncology, Inc., announced the expansion of its leadership team with the appointment of Wendy Li, M.D. as Chief Medical Officer and James Samuels as Chief Financial Officer.

Correvio Pharma Corp. announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 18, 2019.

Harbour BioMed announced the appointment of Kenneth M. Murphy, MD, PhD, to the company’s scientific advisory board. Dr. Murphy, a member of the National Academy of Sciences and a Howard Hughes Medical Institute Investigator, is the Eugene Opie First Centennial Professor of Pathology and Immunology at Washington University.

OrbiMed Advisors LLC has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. and the management of Takeda Pharmaceutical Company Ltd. ahead of the 143rd Ordinary General Meeting of Shareholders that will take place on June 27, 2019, in Yokohama, Japan.

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announces the development of an innovative alternative approach to breath-based testing through the utilization of Exogenous Volatile Organic Compound (EVOC®) Probes